KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other financing activities (2018 - 2025)

Rigel Pharmaceuticals has reported Other financing activities over the past 8 years, most recently at $4.3 million for Q3 2025.

  • Quarterly results put Other financing activities at $4.3 million for Q3 2025, up 2603.16% from a year ago — trailing twelve months through Sep 2025 was $6.6 million (up 573.91% YoY), and the annual figure for FY2024 was $2.0 million, up 87.23%.
  • Other financing activities for Q3 2025 was $4.3 million at Rigel Pharmaceuticals, up from $418000.0 in the prior quarter.
  • Over the last five years, Other financing activities for RIGL hit a ceiling of $4.3 million in Q3 2025 and a floor of $1000.0 in Q1 2023.
  • Median Other financing activities over the past 5 years was $486000.0 (2023), compared with a mean of $852941.2.
  • Biggest five-year swings in Other financing activities: tumbled 99.89% in 2023 and later soared 8800.0% in 2024.
  • Rigel Pharmaceuticals' Other financing activities stood at $1.1 million in 2021, then tumbled by 44.79% to $599000.0 in 2022, then dropped by 18.86% to $486000.0 in 2023, then soared by 201.44% to $1.5 million in 2024, then soared by 191.54% to $4.3 million in 2025.
  • The last three reported values for Other financing activities were $4.3 million (Q3 2025), $418000.0 (Q2 2025), and $484000.0 (Q1 2025) per Business Quant data.